The board of ALPHAMAB-B (09966) has been informed by Dr. Ting Xu, the company's controlling shareholder, Chief Executive Officer, and Executive Director, that on June 4, 2026, he used his own funds to purchase a total of 554,000 ordinary shares of the company on the open market.

Additionally, several members of the company's management purchased a total of 122,000 shares on the open market on June 4, 2026, and in the preceding weeks.

The total consideration for all shares purchased by Dr. Xu and the relevant management members was HK$4.985 million, representing an average purchase price of approximately HK$7.375 per share.

Following this share acquisition, Dr. Xu holds a total of 314 million shares directly and indirectly, representing approximately 32.4% of the company's total issued shares (excluding treasury shares).

Dr. Xu stated that this share purchase is based on the board and management's firm confidence in the company's future prospects and long-term development, believing the current trading price does not reflect the company's intrinsic value.

Specifically, the company's product KN026 for second-line and above treatment of HER2+ GC/GEJ was approved for marketing in China in May 2026, and the significant results from the Phase III clinical study of KN026 for neoadjuvant treatment of HER2+ BC were presented as a Late-Breaking Abstract oral presentation at the 2026 ASCO Annual Meeting.

Currently, multiple registration clinical studies for various indications are progressing smoothly, including KN026 for first-line HER2+ BC, neoadjuvant and adjuvant therapy for HER2+ BC, and first-line HER2+ GC/GEJ; JSKN003 for second-line HER2+ BC, second-line and above HER2-low BC, PROC in all populations, and HER2+ CRC; and JSKN016 for later-line TNBC.

Multiple combination therapy studies for JSKN016 and multiple Phase II clinical studies for JSKN033 are also advancing smoothly.

Patient enrollment for the company's other early-stage ADC products, such as JSKN022, JSKN027, and JSKN021, is being actively promoted.

JSKN022 has already enrolled over 30 patients and has demonstrated preliminary safety and efficacy.

For all products in the pipeline, the company is actively exploring multiple global development strategies.

The company will continue to accelerate the advancement of its clinical programs to create sustained value for patients and shareholders.

Subject to compliance with applicable laws and regulations, Dr. Xu and the relevant management members do not rule out the possibility of further increasing their shareholdings in the company at an appropriate time.